Home > Cellulaire therapie > Allogene stamceltransplantatie > Chronic graft versus host disease (cGVHD) > EFC17757/ROCKnrol-1

EFC17757/ROCKnrol-1

A randomized, double-blind, multicentre, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD).

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 31-10-2024, 11:10